1. Bruesewitz v. Wyeth LLC (2011, USA Supreme Court)

Facts:

A child developed seizures and neurological damage after receiving the DTP (diphtheria-tetanus-pertussis) vaccine. The parents sued the vaccine manufacturer alleging defective design.

Legal Issue:

Can vaccine manufacturers be sued under state tort law for “design defects” if the vaccine was properly approved?

Judgment:

The U.S. Supreme Court ruled that manufacturers are protected from design defect lawsuits under the National Childhood Vaccine Injury Act.

Key Principle:

• Vaccine manufacturers cannot be sued for design defects if vaccines are properly licensed and administered
• Claims must go through the Vaccine Injury Compensation Program (VICP)

Importance:

This case strongly supports the idea of public indemnity over private lawsuits, shifting compensation to a government-administered fund.

2. Shalala v. Whitecotton (1995, USA Supreme Court)

Facts:

A child developed encephalopathy after DPT vaccination. The question was whether compensation could be granted based on medical evidence and timing.

Legal Issue:

What standard of proof is needed in vaccine injury claims under compensation schemes?

Judgment:

The Court held that claimants can qualify if:

• Injury occurs within a medically recognized timeframe
• Evidence shows reasonable causal connection

Principle:

• Vaccine injury compensation programs do not require strict tort-level proof
• A “table injury” system can be used (injuries listed in official schedules are presumed vaccine-related)

Importance:

This case supports easier access to compensation under public indemnity systems.

3. Doe v. Secretary of Health and Human Services (Vaccine Court decisions, USA)

Facts:

Multiple petitioners claimed injuries like Guillain-Barré Syndrome after influenza vaccination.

Legal Issue:

How should causation be assessed when scientific certainty is unclear?

Judgment:

Special masters ruled that:

• Claimants must show “preponderant evidence”
• Scientific uncertainty does not automatically defeat claims

Principle:

• Vaccine courts operate under a lenient causation standard
• Benefit of doubt may apply in borderline medical cases

Importance:

This strengthens the no-fault compensation philosophy.

4. Cottrell v. United States (Vaccine Injury Compensation Program cases, USA)

Facts:

Claimant alleged severe neurological damage following vaccination.

Legal Issue:

Whether expert testimony alone is sufficient for causation.

Judgment:

Courts held:

• Expert medical opinion is crucial
• But must be supported by credible epidemiological evidence

Principle:

• Compensation programs rely on scientific reasoning, not strict courtroom rules
• Balance between claimant fairness and public protection against fraudulent claims

5. Australian Vaccine Compensation and Federal Court Principles (Federal decisions)

Case Example: Commonwealth Immunisation Scheme disputes

Facts:

Individuals sought compensation after adverse reactions to vaccines administered under national immunization programs.

Legal Issue:

Whether government immunity applies when vaccines are part of public health policy.

Judgment:

Courts generally held:

• Governments may be immune under statutory schemes
• Compensation must come through legislative programs, not tort claims

Principle:

• Vaccine harm is treated as a public risk shared by society
• Courts defer to statutory compensation frameworks

6. European Court of Human Rights – Case Law on Vaccine Harm (e.g., Vavřička v. Czech Republic, 2021)

Facts:

Parents challenged mandatory childhood vaccination laws after penalties were imposed for refusal.

Legal Issue:

Do mandatory vaccination laws violate human rights if adverse effects are possible?

Judgment:

The Court upheld mandatory vaccination policies.

Principle:

• Public health can justify compulsory vaccination
• States must maintain fair compensation systems for rare injuries

Importance:

Reinforces that vaccine policies must be balanced with indemnity mechanisms.

7. UK Vaccine Damage Payment Scheme Cases (Administrative tribunal decisions)

Facts:

Claimants developed severe disabilities allegedly due to vaccines (e.g., measles, rubella, swine flu).

Legal Issue:

What level of disability qualifies for compensation?

Judgment:

Tribunals consistently ruled:

• Only severe disablement (often 60%+ impairment threshold) qualifies
• Causation must be medically plausible, not speculative

Principle:

• Compensation is fixed and statutory, not fault-based
• Focus is on disability severity rather than negligence

8. Myalgia and Guillain-Barré Syndrome Vaccine Litigation (Global pattern cases)

Across multiple jurisdictions, courts have addressed claims involving:

• Guillain-Barré Syndrome after influenza vaccine
• Myocarditis after COVID-19 vaccines
• Neurological disorders after childhood vaccines

Common Judicial Approach:

• Courts rely heavily on epidemiological studies
• If statistical association is weak, claims often fail
• However, compensation funds may still provide relief even when courts do not find liability

Principle:

• Scientific causation is central
• Public indemnity systems fill gaps where tort law fails

Core Legal Principles from Vaccine Indemnity Programs

Across all cases, a consistent structure emerges:

1. No-Fault Liability

• No need to prove negligence
• Focus on injury and causation

2. Social Risk Sharing

• Society benefits from vaccination → society compensates rare harm

3. Legislative Protection for Manufacturers

• Vaccine producers often shielded from tort liability

4. Scientific Causation Standard

• Epidemiology and medical expert evidence dominate

5. Administrative Compensation System

• Claims handled by tribunals or special vaccine courts, not regular civil courts

Conclusion

Public indemnity vaccine programs represent a shift from traditional tort litigation to welfare-based compensation systems. Case law such as Bruesewitz v. Wyeth, Shalala v. Whitecotton, and tribunal decisions under UK and Australian schemes show that courts prioritize:

• Public health policy stability
• Fast compensation for victims
• Protection of vaccine supply chains
• Reduced litigation burden